Isomorphic Labs

Isomorphic Labs, a London-based company leveraging artificial intelligence for drug discovery, has successfully closed a Series B funding round, raising £1.6 billion.

Summary of transaction details:

• Value: £1.6 billion
• Sector: Healthcare & Biotech
• Advisor: Not specified
• Key Entities: Isomorphic Labs (Target), Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund (Investors)
• Location: London (Target HQ)

Note: This substantial investment underscores the increasing strategic importance and commercial viability of AI applications in accelerating and enhancing the drug discovery process within the pharmaceutical industry.